Key facts
- This page summarizes Yong Chan Kim's Form 3 filing for Baudax Bio, Inc..
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Jul 2023, 16:21.
Yong Chan Kim - 03 Jul 2023 Form 3 Insider Report for Baudax Bio, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 03 Jul 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jillian Dilmore, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Yong Chan Kim filed Form 3 for Baudax Bio, Inc. on 13 Jul 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BXRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 202,260
- Date
- 03 Jul 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BXRX
holding
Derivative
Series X Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,520,066
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares of Series X Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series X Preferred Stock"), shall automatically convert into the Issuer's common stock based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designations of Series X Non-Voting Convertible Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on July 5, 2023), effective as of 5:00 p.m. Eastern Time on the second trading day after the date on which the Issuer's stockholders approve the conversion of the Series X Preferred Stock.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney